New York, NY (June 8, 2011) – Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have been selected to conduct a Phase 2 clinical research study of an investigational medication in patients with Major Depressive Disorder.
The trial will examine the effects of an investigational medication in treatment resistant patients who are experiencing a current episode of depression. This is Clinilabs’ fifth study in this therapeutic area. Dr. Stephen Murray, Clinilabs’ Chief Medical Officer states: “Major Depressive Disorder is a debilitating disease that carries with it both emotional and physical symptoms. I am pleased to be involved in a clinical trial that is assessing a novel medication that may combat this condition.”
Enrollment for this study has begun. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who suffer from Major Depressive Disorder can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/mdd.
About Clinilabs Inc.
Clinilabs is a full-service contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.
For more information or to schedule an interview, please contact Hannah D’Aoust at 646.215.6411 or e-mail hdaoust@clinilabs.com.
